Immuron (IMRN) Research & Development (2016 - 2024)
Immuron's quarterly Research & Development came in at -$1296.2 billion in Q4 2024, down 48857378.76% year-on-year from N/an in Q1 2024, and down 48857378.76% quarter-over-quarter from -$2.7 million in Q4 2023.
Immuron has reported Research & Development for 9 years, with the latest figure at -$1296.2 billion in Q4 2024.
- For the quarter ending Q4 2024, Research & Development fell 48857378.76% year-over-year to -$1296.2 billion; the trailing twelve-month figure through Dec 2024 stood at -$1296.2 billion (down 32170207.19% YoY), and the FY2025 full-year result was $2.3 million, down 33.87% from the prior year.
- Research & Development for Q4 2024 stood at -$1296.2 billion, down from -$2.7 million in the prior quarter.
- The five-year high for Research & Development was $148106.7 in Q2 2023, with the low at -$1296.2 billion in Q4 2024.
- Average Research & Development over 5 years is -$216.0 billion, with a median of -$765270.4 recorded in 2020.
- Year-over-year, Research & Development jumped 69.96% in 2021 and sank 48857378.76% in 2024.
- Tracing IMRN's Research & Development over 5 years: stood at -$8905.8 in 2020, then jumped by 69.96% to -$2675.6 in 2021, then plunged by 56770.31% to -$1.5 million in 2022, then sank by 74.36% to -$2.7 million in 2023, then slumped by 48857378.76% to -$1296.2 billion in 2024.
- The last three Research & Development figures came in at -$1296.2 billion (Q4 2024), -$2.7 million (Q4 2023), and $148106.7 (Q2 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Immuron | 1.27 Bn | 1.27 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -1,296.23 Bn |
| Dec 31, 2023 | -2.65 Mn |
| Jun 30, 2023 | 148,106.67 |
| Dec 31, 2022 | -1.52 Mn |
| Dec 31, 2021 | -2,675.62 |
| Dec 31, 2020 | -8,905.75 |
| Dec 31, 2019 | -7,614.21 |
| Dec 31, 2018 | -514,388.00 |
| Dec 31, 2017 | -1.20 Mn |
| Dec 31, 2016 | -1.60 Mn |
| Jun 30, 2016 | -2.71 Mn |